Relmada Therapeutics (RLMD) Other Accumulated Expenses (2019 - 2026)
Relmada Therapeutics (RLMD) reported Other Accumulated Expenses of $76100.0 for Q1 2026, up 12.57% year-over-year from $67600.0 in Q1 2025, and down 43.38% on a QoQ basis from $134400.0 in Q4 2025.
Relmada Therapeutics (RLMD) has 6 years of Other Accumulated Expenses data on file, last reported at $76100.0 in Q1 2026.
- Quarterly Other Accumulated Expenses rose 12.57% year-over-year to $76100.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76100.0 (up 12.57% YoY) and the FY2025 annual result came in at $134400.0, up 3.86% from the prior year.
- Other Accumulated Expenses fell to $76100.0 in Q1 2026 per RLMD's latest filing, from $134400.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $134400.0 in Q4 2025 and bottomed at $67600.0 in Q1 2025.
- The 4-year median for Other Accumulated Expenses is $80600.0 (2024), against an average of $95450.0.
- The widest annual swing landed in 2025, when Other Accumulated Expenses climbed 0.75%; it then gained 12.57% in 2026.
- Tracing RLMD's Other Accumulated Expenses over 4 years: stood at $115500.0 in 2023, then grew by 12.03% to $129400.0 in 2024, then gained by 3.86% to $134400.0 in 2025, then plunged by 43.38% to $76100.0 in 2026.
- Per Business Quant, the three latest RLMD Other Accumulated Expenses figures stand at $76100.0 (Q1 2026), $134400.0 (Q4 2025), and $80900.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76,100.00 |
| Dec 31, 2025 | 134,400.00 |
| Sep 30, 2025 | 80,900.00 |
| Jun 30, 2025 | 79,400.00 |
| Mar 31, 2025 | 67,600.00 |
| Dec 31, 2024 | 129,400.00 |
| Sep 30, 2024 | 80,300.00 |
| Dec 31, 2023 | 115,500.00 |
| Dec 31, 2020 | 126,200.00 |
| Jun 30, 2020 | 65,900.00 |
| Dec 31, 2019 | 92,900.00 |
| Sep 30, 2019 | 65,200.00 |
| Jun 30, 2019 | 59,400.00 |